Jane Street Group LLC Decreases Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Jane Street Group LLC cut its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 89.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 50,557 shares of the company’s stock after selling 442,699 shares during the quarter. Jane Street Group LLC owned 0.11% of Omnicell worth $2,204,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC grew its stake in shares of Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after acquiring an additional 600 shares in the last quarter. Arkadios Wealth Advisors increased its stake in Omnicell by 15.1% during the second quarter. Arkadios Wealth Advisors now owns 34,530 shares of the company’s stock worth $935,000 after acquiring an additional 4,520 shares during the last quarter. Panagora Asset Management Inc. raised its position in Omnicell by 1.6% during the second quarter. Panagora Asset Management Inc. now owns 75,799 shares of the company’s stock valued at $2,052,000 after purchasing an additional 1,204 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Omnicell by 3.0% in the 2nd quarter. Rhumbline Advisers now owns 147,188 shares of the company’s stock valued at $3,984,000 after purchasing an additional 4,281 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of OMCL opened at $44.50 on Tuesday. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -114.10, a PEG ratio of 34.96 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a 50-day moving average of $45.55 and a 200 day moving average of $39.55.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.64% of the company’s stock.

Analyst Ratings Changes

OMCL has been the topic of several recent research reports. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America reaffirmed a “neutral” rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Barclays upped their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Craig Hallum boosted their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.